Search / Trial NCT06227975

A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants

Launched by CELGENE · Jan 19, 2024

Trial Information

Current as of October 07, 2024

Completed

Keywords

Adme Healthy Male Volunteers Pharmacokinetics Bms 986368 Cc 97489

Description

No description provided

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • * Healthy male participants as determined by no clinically significant deviations from normal in medical history, physical examination, vital signs, 12-lead ECGs, and clinical laboratory determinations, as assessed by the investigator.
  • * Body mass index of 18.0 to 35.0 kg/m2, inclusive. Body mass index = weight (kg)/(height\[m\])\^2
  • Exclusion Criteria:
  • * History of hypokalemia.
  • * Any significant acute or chronic medical illness as determined by the investigator.
  • * Participant has a history of syncope in the year prior to Day 1.
  • Other protocol-defined incusion/exclusion criteria apply.

About Celgene

Celgene, now a part of Bristol Myers Squibb, is a global biopharmaceutical company dedicated to advancing innovative therapies for patients with cancer and other serious diseases. With a strong emphasis on research and development, Celgene focuses on discovering and delivering transformative medicines that address unmet medical needs. The company is committed to enhancing patient outcomes through rigorous clinical trials, cutting-edge science, and collaboration with healthcare professionals, ultimately striving to improve the quality of life for patients worldwide.

Locations

Madison, Wisconsin, United States

Madison, Wisconsin, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0